

01 September 2026

## Analysis On Treatment With Immunology Medicines

I would be grateful if you could tell me how many patients were treated in the 3 months between April and June 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

**Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1<sup>st</sup> April 2026 and 30<sup>th</sup> June 2026, or the latest 3-month period for which you have data?**

| Drug Name          | <b><u>Total</u></b> number of patients treated<br><b><u>regardless of diagnosis</u></b> |
|--------------------|-----------------------------------------------------------------------------------------|
| Adalimumab         | 1398                                                                                    |
| Abrocitinib        | 10                                                                                      |
| Apremilast         | <5                                                                                      |
| Baricitinib        | 32                                                                                      |
| Bimekizumab        | 92                                                                                      |
| Brodalumab         | 0                                                                                       |
| Certolizumab Pegol | 153                                                                                     |
| Deucravacitinib    | <5                                                                                      |
| Dupilumab          | 299                                                                                     |
| Etanercept         | 439                                                                                     |
| Guselkumab         | 109                                                                                     |
| Infliximab         | 128                                                                                     |
| Ixekizumab         | 191                                                                                     |
| Lebrikizumab       | 20                                                                                      |
| Nemolizumab        | 13                                                                                      |
| Risankizumab       | 111                                                                                     |
| Secukinumab        | 309                                                                                     |
| Tildrakizumab      | <5                                                                                      |
| Tralokinumab       | 0                                                                                       |
| Ustekinumab        | 109                                                                                     |

01 September 2026

**Q2. How many patients were treated by the Dermatology or Rheumatology Departments or Clinics with the following drugs between 1<sup>st</sup> April 2026 and 30<sup>th</sup> June 2026, or the latest 3-month period for which you have data?**

| Drug Name          | Number of patients treated by the <u>Dermatology Department</u> | Number of patients treated by the <u>Rheumatology Department</u> |
|--------------------|-----------------------------------------------------------------|------------------------------------------------------------------|
| Adalimumab         | 325                                                             | 1073                                                             |
| Apremilast         | <5                                                              | 0                                                                |
| Baricitinib        | <5                                                              | 30                                                               |
| Bimekizumab        | 18                                                              | 74                                                               |
| Brodalumab         | 0                                                               | 0                                                                |
| Certolizumab Pegol | 7                                                               | 146                                                              |
| Etanercept         | <5                                                              | 435                                                              |
| Guselkumab         | 94                                                              | 15                                                               |
| Infliximab         | 13                                                              | 115                                                              |
| Ixekizumab         | 65                                                              | 126                                                              |
| Risankizumab       | 110                                                             | <5                                                               |
| Secukinumab        | 68                                                              | 241                                                              |
| Ustekinumab        | 105                                                             | <5                                                               |

**Q3. How many patients with Plaque Psoriasis or Psoriatic Arthritis across all departments were treated with the following drugs between 1<sup>st</sup> April 2026 and 30<sup>th</sup> June 2026, or the latest 3-month period for which you have data?**

| Drug Name          | Number patients with Plaque Psoriasis | Number patients with Psoriatic Arthritis |
|--------------------|---------------------------------------|------------------------------------------|
| Adalimumab         | 273                                   | 954                                      |
| Bimekizumab        | 17                                    | 73                                       |
| Secukinumab        | 50                                    | 201                                      |
| Apremilast         | <5                                    | 0                                        |
| Certolizumab Pegol | 7                                     | 104                                      |
| Etanercept         | <5                                    | 386                                      |
| Guselkumab         | 94                                    | 13                                       |
| Infliximab         | <5                                    | 102                                      |
| Ixekizumab         | 65                                    | 101                                      |
| Risankizumab       | 110                                   | <5                                       |
| Ustekinumab        | 104                                   | <5                                       |
| Brodalumab         | 0                                     | 0                                        |
| Deucravacitinib    | <5                                    | 0                                        |

01 September 2026

**Q4. How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1<sup>st</sup> April 2026 and 30<sup>th</sup> June 2026, or the latest 3-month period for which you have data?**

| Drug Name   | <u>Atopic Dermatitis</u> |
|-------------|--------------------------|
| Baricitinib | <5                       |
| Dupilumab   | 289                      |
| Nemolizumab | 13                       |

**Q5. How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1<sup>st</sup> April 2026 and 30<sup>th</sup> June 2026, or the latest 3-month period for which you have data?**

| Drug Name   | <u>Hidradenitis Suppurativa</u> |
|-------------|---------------------------------|
| Adalimumab  | 53                              |
| Bimekizumab | <5                              |
| Secukinumab | 17                              |

\*Some figures have been withheld and replaced with less than five (<5), this is due to the small geographical area of NI and releasing the actual figure has the potential to make the patient identifiable.